Aster DM Quality Care to invest Rs 1,315 crore in Karnataka

Aster DM Quality Care will invest Rs 1,315 crore in Karnataka's healthcare infrastructure. This significant investment aims to strengthen the state's medical facilities and services. The company plans to develop new hospitals and expand existing ones in Bengaluru. These developments will enhance access to advanced tertiary and quaternary care. The commitment underscores Aster's long-term confidence in Karnataka's healthcare ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gX19DFN
via IFTTT

Read More

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company aims for significant revenue growth by 2030 through new drug launches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/deDbnmy
via IFTTT

Read More

FSSAI suspends Rehaan Healthcare licence over serious food safety violations

FSSAI has suspended Rehaan Healthcare’s licence after inspections revealed serious violations at its health supplements and nutraceutical manufacturing facility. The regulator found extremely unhygienic conditions, poor infrastructure, pest infestation, inadequate storage, and major food safety lapses, resulting in a very low compliance score of 12%. The company has been ordered to halt production until all deficiencies are rectified and verified by the competent authority, failing which legal action may follow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u5PjhQJ
via IFTTT

Read More

Jackson Labs seeks restoration of its licence

The cancellation issued by the Punjab government followed reports that five women in Kota, Rajasthan, died after allegedly being administered an Oxytocin injection that upon testing found contained no active ingredient.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T9z30Rj
via IFTTT

Read More

India contributes one-third of global oral cancer burden; early detection key to survival, says oral cancer expert

India contends with a pressing oral cancer crisis, with thousands of new diagnoses and deaths emerging annually. The predominant factor behind this disease is the consumption of tobacco in diverse forms. Early detection via screening plays a critical role in managing and treating oral cancers successfully. It’s vital to monitor potentially malignant disorders closely and seek rapid medical assistance for ongoing oral health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8OHqfZa
via IFTTT

Read More

Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practical

US President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export significant generic medicines to the United States market. The proposed tariffs are set to begin in 2028, offering a two-year window. This lead time allows Indian firms to explore alternative export markets and adapt. American patients and insurers will likely face increased healthcare costs after tariffs are imposed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WvB3al9
via IFTTT

Read More

Dr Reddy’s aims to resume semaglutide supply by November after API fix

Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xl093uB
via IFTTT

Read More